Introduction
The targeted therapies market is relatively new in comparison to the cytotoxic and anti-hormonal therapies markets, and will therefore continue to show double-figure growth across the seven major pharmaceutical markets to 2014. Despite products which have already established gold-standard status within specific tumor types, ample lucrative opportunities exist for pipeline candidates in the market.

Scope
Overview of the current targeted therapies market, including profiles of key products and events impacting each during 200414
Examination of the targeted therapies pipeline with in-depth clinical and commercial profiles of Phase III candidates, plus expert opinion
Seven-market sales forecasts from 2004 to 2014 for branded targeted therapies and key pipeline candidates
Detailed discussion of key strategic issues in the targeted therapies market, plus three commercial impact and lifecycle management case studies
Highlights
The market for existing targeted therapies was worth $5.1 billion in 2004, and is set to grow at a CAGR of 13.7% to reach $13.7 billion by 2014. This is due to the novelty of this market, allowing for further increasing sales of current marketed products, with no immediate threat from patent expiries and generic competition.

This sustained growth will allow established products such as Genentech/Roche's Rituxan and Novartis' Glivec to maintain their blockbuster status, while allowing newer products such as Genentech/Roche's Herceptin, Avastin and Tarceva to break the $1 billion sales barrier within the forecast period.

The introduction of high-potential pipeline products will increase the total market value of targeted therapies to $19.2 billion by 2014. Those products developed to inhibit multiple pathways show the most promise, particularly Onyx Pharmaceuticals/Bayer's sorafenib and Bristol-Myers Squibb's dasatinib, with forecast sales of over $800m by 2014.

Reasons to Purchase
Understand market specific drivers and predict the future potential of key marketed and pipeline targeted therapies
Assess the impact of product launches and identify the opportunities and risks for key products within the targeted therapies market
Adopt knowledge to drive strategic planning for marketed products and optimize the market penetration of new entrants

Introduction
The targeted therapies market is relatively new in comparison to the cytotoxic and anti-hormonal therapies markets, and will therefore continue to show double-figure growth across the seven major pharmaceutical markets to 2014. Despite products which have already established gold-standard status within specific tumor types, ample lucrative opportunities exist for pipeline candidates in the market.

Scope
Overview of the current targeted therapies market, including profiles of key products and events impacting each during 200414
Examination of the targeted therapies pipeline with in-depth clinical and commercial profiles of Phase III candidates, plus expert opinion
Seven-market sales forecasts from 2004 to 2014 for branded targeted therapies and key pipeline candidates
Detailed discussion of key strategic issues in the targeted therapies market, plus three commercial impact and lifecycle management case studies
Highlights
The market for existing targeted therapies was worth $5.1 billion in 2004, and is set to grow at a CAGR of 13.7% to reach $13.7 billion by 2014. This is due to the novelty of this market, allowing for further increasing sales of current marketed products, with no immediate threat from patent expiries and generic competition.

This sustained growth will allow established products such as Genentech/Roche's Rituxan and Novartis' Glivec to maintain their blockbuster status, while allowing newer products such as Genentech/Roche's Herceptin, Avastin and Tarceva to break the $1 billion sales barrier within the forecast period.

The introduction of high-potential pipeline products will increase the total market value of targeted therapies to $19.2 billion by 2014. Those products developed to inhibit multiple pathways show the most promise, particularly Onyx Pharmaceuticals/Bayer's sorafenib and Bristol-Myers Squibb's dasatinib, with forecast sales of over $800m by 2014.

Reasons to Purchase
Understand market specific drivers and predict the future potential of key marketed and pipeline targeted therapies
Assess the impact of product launches and identify the opportunities and risks for key products within the targeted therapies market
Adopt knowledge to drive strategic planning for marketed products and optimize the market penetration of new entrants